JP2016503301A - 侵攻性前立腺癌の存在または不存在を判定する方法 - Google Patents

侵攻性前立腺癌の存在または不存在を判定する方法 Download PDF

Info

Publication number
JP2016503301A
JP2016503301A JP2015542308A JP2015542308A JP2016503301A JP 2016503301 A JP2016503301 A JP 2016503301A JP 2015542308 A JP2015542308 A JP 2015542308A JP 2015542308 A JP2015542308 A JP 2015542308A JP 2016503301 A JP2016503301 A JP 2016503301A
Authority
JP
Japan
Prior art keywords
category
pca
biomarker
composite value
snppc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503301A5 (enExample
Inventor
ヘンリク・グレンバリ
マルティン・エクルンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Phadia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phadia AB filed Critical Phadia AB
Publication of JP2016503301A publication Critical patent/JP2016503301A/ja
Publication of JP2016503301A5 publication Critical patent/JP2016503301A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2015542308A 2012-11-20 2013-11-20 侵攻性前立腺癌の存在または不存在を判定する方法 Pending JP2016503301A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1251312-3 2012-11-20
SE1251312 2012-11-20
SE1350600 2013-05-16
SE1350600-1 2013-05-16
PCT/EP2013/074259 WO2014079865A1 (en) 2012-11-20 2013-11-20 Method for indicating a presence or non-presence of aggressive prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018189147A Division JP2019049559A (ja) 2012-11-20 2018-10-04 侵攻性前立腺癌の存在または不存在を判定する方法

Publications (2)

Publication Number Publication Date
JP2016503301A true JP2016503301A (ja) 2016-02-04
JP2016503301A5 JP2016503301A5 (enExample) 2017-01-05

Family

ID=49619938

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015542308A Pending JP2016503301A (ja) 2012-11-20 2013-11-20 侵攻性前立腺癌の存在または不存在を判定する方法
JP2018189147A Pending JP2019049559A (ja) 2012-11-20 2018-10-04 侵攻性前立腺癌の存在または不存在を判定する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018189147A Pending JP2019049559A (ja) 2012-11-20 2018-10-04 侵攻性前立腺癌の存在または不存在を判定する方法

Country Status (14)

Country Link
US (1) US10431326B2 (enExample)
EP (2) EP2922967B1 (enExample)
JP (2) JP2016503301A (enExample)
KR (1) KR20150110477A (enExample)
AU (1) AU2013349801B2 (enExample)
BR (1) BR112015011359B1 (enExample)
CA (2) CA2891392C (enExample)
DK (1) DK2922967T3 (enExample)
ES (1) ES2667326T3 (enExample)
IL (1) IL238724A0 (enExample)
MY (1) MY182773A (enExample)
RU (1) RU2675370C2 (enExample)
WO (1) WO2014079865A1 (enExample)
ZA (1) ZA201503460B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505928A (ja) * 2017-02-01 2020-02-27 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
JP2022039186A (ja) * 2020-08-28 2022-03-10 国立研究開発法人理化学研究所 前立腺がんの検査方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3312749T3 (fi) 2012-03-05 2024-05-31 Oy Arctic Partners Ab Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen
CA2891394C (en) 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer
FI3117216T3 (fi) 2014-03-11 2023-04-27 Phadia Ab Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
US12326453B2 (en) * 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
US9858665B2 (en) * 2015-04-03 2018-01-02 Regents Of The University Of Minnesota Medical imaging device rendering predictive prostate cancer visualizations using quantitative multiparametric MRI models
EP3287786A3 (en) * 2015-04-29 2018-03-21 Opko Diagnostics, LLC Compositions and methods for active surveillance of prostate cancer
WO2017164699A1 (ko) * 2016-03-24 2017-09-28 서울대학교병원 (분사무소) 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
DK3270163T3 (en) * 2016-07-15 2018-11-19 Proteomedix Ag PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES
KR102093453B1 (ko) * 2018-01-08 2020-03-25 (주)인실리코젠 체형 및 대사 감수성 snp 마커 및 진단정보 제공방법
CN111712878A (zh) 2018-01-22 2020-09-25 法迪亚股份公司 用于协调分析结果的方法
IT201800021394A1 (it) * 2018-12-28 2020-06-28 Daniela Terracciano Metodo in vitro per la diagnosi del cancro alla prostata
US11633146B2 (en) 2019-01-04 2023-04-25 Regents Of The University Of Minnesota Automated co-registration of prostate MRI data
US11631171B2 (en) 2019-01-10 2023-04-18 Regents Of The University Of Minnesota Automated detection and annotation of prostate cancer on histopathology slides
CN109628564B (zh) * 2019-02-25 2022-02-01 北京市理化分析测试中心 一种用于检测snp多态性的引物组和利用引物组检测snp多态性的方法
KR102068667B1 (ko) * 2019-02-28 2020-01-21 주식회사 프로카젠 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371654B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102068666B1 (ko) * 2019-02-28 2020-02-11 주식회사 프로카젠 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371655B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
IT202000029948A1 (it) * 2020-12-04 2022-06-04 Nib Biotec S R L Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età
GB2599198B (en) * 2021-06-15 2022-12-07 A3P Biomedical Ab A method for determining an appropriate time interval for further diagnostic testing for prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219840A1 (en) 2002-05-24 2003-11-27 Mikolajczyk Stephen D. Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
WO2010081240A1 (en) 2009-01-19 2010-07-22 Miraculins Inc. Diagnostic assays for prostate cancer using psp94 and psa biomarkers
US20120121618A1 (en) 2009-02-12 2012-05-17 Dana-Farber Cancer Institute, Inc. Predicting And Treating Prostate Cancer
WO2011150515A1 (en) 2010-06-01 2011-12-08 Universite Laval Prognostic markers for prostate cancer recurrence
US9732389B2 (en) * 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) * 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
JP2015524052A (ja) * 2012-05-16 2015-08-20 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 前立腺癌の存在または不存在の提示方法
CA2891394C (en) 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIOMED RESEARCH INTERNATIONAL, vol. 2014, JPN6017039895, 2014, pages 526341, ISSN: 0003667017 *
BMC MEDICINE, vol. 6, JPN6017039877, 2008, pages 19, ISSN: 0003667009 *
CARCINOGENESIS, vol. 32, no. 7, JPN6017039890, 2011, pages 1057 - 1062, ISSN: 0003667014 *
EUROPEAN UROLOGY, vol. 60, JPN6017039883, 2011, pages 21 - 28, ISSN: 0003667011 *
EUROPEAN UROLOGY, vol. 62, JPN6017039885, May 2012 (2012-05-01), pages 953 - 961, ISSN: 0003667012 *
HUMAN MOLECULAR GENETICS, vol. 22, no. 2, JPN6017039892, 2013, pages 408 - 415, ISSN: 0003667015 *
JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 96, no. 16, JPN6017039879, 2004, pages 1248 - 1254, ISSN: 0003667010 *
LANCET ONCOL., vol. 16, JPN6017039897, 2015, pages 1667 - 76, ISSN: 0003667018 *
PNAS, vol. 107, no. 5, JPN6017039887, 2010, pages 2136 - 2140, ISSN: 0003667013 *
UROLOGIC ONCOLOGY, vol. 35, JPN6017039898, 2017, pages 120, ISSN: 0003667019 *
生物試料分析, vol. 35, no. 1, JPN6017039901, December 2012 (2012-12-01), pages 95, ISSN: 0003667016 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505928A (ja) * 2017-02-01 2020-02-27 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
JP7138112B2 (ja) 2017-02-01 2022-09-15 ファディア・アクチボラゲット 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
JP2022179483A (ja) * 2017-02-01 2022-12-02 ファディア・アクチボラゲット 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
JP2022039186A (ja) * 2020-08-28 2022-03-10 国立研究開発法人理化学研究所 前立腺がんの検査方法
JP7641532B2 (ja) 2020-08-28 2025-03-07 国立研究開発法人理化学研究所 前立腺がんの検査方法

Also Published As

Publication number Publication date
HK1215594A1 (en) 2016-09-02
AU2013349801B2 (en) 2019-03-07
MY182773A (en) 2021-02-05
CA3092807A1 (en) 2014-05-30
EP2922967B1 (en) 2018-01-03
RU2015124054A (ru) 2017-01-10
DK2922967T3 (en) 2018-04-16
EP3327146A1 (en) 2018-05-30
WO2014079865A1 (en) 2014-05-30
US20150317431A1 (en) 2015-11-05
BR112015011359B1 (pt) 2022-12-06
AU2013349801A1 (en) 2015-05-28
CA2891392C (en) 2020-11-03
CA3092807C (en) 2024-02-27
RU2675370C2 (ru) 2018-12-19
EP2922967A1 (en) 2015-09-30
CA2891392A1 (en) 2014-05-30
KR20150110477A (ko) 2015-10-02
IL238724A0 (en) 2015-06-30
ES2667326T3 (es) 2018-05-10
BR112015011359A2 (pt) 2017-07-11
BR112015011359A8 (pt) 2019-10-01
JP2019049559A (ja) 2019-03-28
ZA201503460B (en) 2018-11-28
US10431326B2 (en) 2019-10-01
CN105051206A (zh) 2015-11-11

Similar Documents

Publication Publication Date Title
DK2922967T3 (en) PROCEDURE FOR VIEWING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATANCES
US10451626B2 (en) Method for detecting a solid tumor cancer
US20200010912A1 (en) Prognostic method for individuals with prostate cancer
JP2022179483A (ja) 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法
CN105051206B (zh) 用于指示侵袭性前列腺癌的存在或不存在的方法
HK1215594B (en) Method for indicating a presence or non-presence of aggressive prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180605